Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million
05:45 EST 12 Dec 2012 | thePharmaLetter
Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's strategy for the next five years at a briefing in New York, promising up to $2 billion in cost reductions, acquisitions and the divestment of non..
Original Article: Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million
More From BioPortfolio on "Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
